{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060028","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.841335+00:00","generated_at":"2026-06-01T23:51:14.753865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Therapeutics reports Q1 net loss $12.3M ($0.02/sh); cash $180.6M after $177M raise","bullets":["Net loss $12.3M for Q1 2024 vs $0.4M year ago; R&D expense rose 127% to $7.5M.","Cash, equivalents & short-term investments $180.6M at March 31 vs $9.2M at Dec 31; additional $49.5M raised via ATM in April.","Raised $177.2M gross from public/private offerings including $20.8M private placement and Lantheus investment.","Phase 1/2a for [212Pb]VMT-α-NET dosed 9 patients; combo trial with Bristol Myers' nivolumab for VMT01 in melanoma planned.","Disclosed new pre-IND asset PSV359 targeting FAP-α; IND expected late 2024; brachytherapy divested to GT Medical."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060028","json":"https://secwatch.observer/filing/0000950170-24-060028.json","markdown":"https://secwatch.observer/filing/0000950170-24-060028.md","text":"https://secwatch.observer/filing/0000950170-24-060028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/0000950170-24-060028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/catx-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:51:14.753865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0e24a061bd4c20fdbf740a4263016bb9f683fdd","claim":"Perspective Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 15, 2024, Perspective Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000095017024060028/0000950170-24-060028-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}